LL LLY Eli Lilly and Company 로딩 중... : 애널리스트의 강세 및 약세 의견

BD has signed over 80 GLP-1 biosimilar deals that will use its devices, with auto-injectors/pens carrying several times the ASP of syringes, making biosimilars a higher-value opportunity than the current novel GLP-1 market. — As GLP-1 biosimilars enter the market, BD's per-dose economics will improve substantially, making it a key supplier to the coming biosimilar wave and a hedge against oral GLP-1 disruption.